(2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them
The present invention relates to novel (2R)-2-phenylpropanamides bearing a 4-sulfonylamino substituent on the 4 position of the phenyl group and to pharmaceutical compositions containing them, which are used as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells, and which are useful in the treatment of various ELR+CXC chemokine-mediated disorders. In particular, the compounds of the invention are useful in the treatment and control of specific CXCR2 dependent pathologies such as BOS, COPD, angiogenesis and melanoma.
1. A method for the treatment of melanoma that involve CXCL1 induced human PMNs chemotaxis said method comprising administering to a subject in need thereof an effective amount of (2R)-phenylpropanamidederivatives of formula (I):
R is selected from
—H, OH, C 1 -C 5 -alkyl, C 3 -C 6 -cycloalkyl, C 2 -C 5 -alkenyl, C 1 -C 5 -alkoxy and phenyl;
an heteroaryl group selected from substituted and unsubstituted pyrrole, thiophene, furane, indole, imidazole, thiazole, oxazole, pyridine and pirimidine;
a residue of formula —CH 2 —CH 2 —O—(CH 2 —CH 2 O)nR″, wherein R″ is H or C 1 -C 5 -alkyl, n is an integer from 0 to 2;
or R, together with the NH group to which is coupled, is a radical group of primary amides of natural amino acids such as (2S)-2-aminopropanamide, (2S)-2-amino-3-phenylpropanamide, (2S)-2-amino-3-hydroxypropanamide, (2S)-2-amino-3-carboxypropanamide, (2S)-2,6-diaminoexanamide;
R′ is selected from
linear or branched C 1 -C 5 -alkyl, C 3 -C 6 -cycloalkyl, C 2 -C 5 -alkenyl and trifluoromethyl;
substituted or unsubstituted phenyl;
substituted or unsubstituted benzyl;
an heteroaryl group selected from substituted and unsubstituted pyridine, pirimidine, pyrrole, thiophene, furane, indole, thiazole and oxazole.
2. The method according to claim 1 wherein in the (2R)-2 phenylpropanamidederivatives of formula (I)
R is selected from
H, C 1 -C 5 -alkyl, C 3 -C 6 -cycloalkyl, L-2-amino-1-methyl-2-oxoethyl;
an heteroaryl group selected from substituted and unsubstituted thiazole, oxazole, pyridine;
R′ is selected from
linear or branched C 1 -C 5 -alkyl, C 3 -C 6 -cycloalkyl, trifluoromethyl, benzyl;
unsubstituted or substituted phenyl with a group selected from halogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, trifluoromethyl, thiophene.
3. The method according to claim 2 wherein the (2R)-2 phenylpropanamidederivatives of formula (I) is selected from the group consisting of:
(2R)-2-{4-[(isopropylsulfonyl)amino]phenyl}propanamide;
(2R)-2-{4-[(isopropylsulfonyl)amino}phenyl)propanamide sodium salt;
(2R)-2-{4-{[(2-chlorophenyl)sulfonyl]amino}phenyl)propanamide;
(2R)-2-{4-{[(2,6-dichlorophenyl)sulfonyl]amino}phenyl)propanamide;
(2R)-2-{4-[(methylsulfonyl)amino]phenyl}propanamide;
(2R)-2-{4-[(phenylsulfonyl)amino]phenyl}propanamide;
(2R)-2-{4-{[(4-methylphenyl)sulfonyl]amino}phenyl)propanamide;
(2R)-2-{4-{[(4-methoxylphenyl)sulfonyl]amino}phenyl)propanamide;
(2R)-2-(4-[(benzylsulfonyl)amino}phenyl)propanamide;
(2R)-2-(4-{[(4-chlorophenyl)sulfonyl]amino}phenyl)propanamide;
(2R)-2-(4-{[(4-(trifluoromethyl)phenyl]sulfonyl}amino)phenyl]propanamide;
(2R)-2-{4-[(thien-2ylsulfonyl)amino]phenyl}propanamide;
(2R)-2-{4-[(cyclopentylsulfonyl)amino]phenyl}propanamide;
(2R)-2-(4-{[(trifluoromethyl)sulfonyl]amino}phenyl)propanamide;
(2R)-2-{4-[(isopropylsulfonyl)amino}phenyl)-N-methylpropanamide;
(2R)-N-[(1S)-2-amino-1-methyl-2-oxoethyl]-2-{4-[(isopropylsulfonyl]amino}phenyl)propanamide;
(2R)-2-{4-[(isopropylsulfonyl]amino}phenyl)-N-[4-(trifluoromethyl)-1,3-thiazol-2-yl]propanamide;
(2R)-2-{4-{[(2-chlorophenyl)sulfonyl]amino}phenyl)-N-[4-(trifluoromethyl)-1,3-thiazol-2-yl]propanamide;
(2R)-2-{4-{[(2-chlorophenyl)sulfonyl]amino}phenyl)-N-[2-(2-hydroxyethoxy)ethyl]propanamide;
(2R)-2-{4-{[(2-chlorophenyl)sulfonyl]amino}phenyl)-N-cyclopropylpropanamide.
4. The method according to claim 1 , wherein the (2R)-2 phenylpropanamidederivatives of formula (I) is administered in dosage range of from 1 to 1500 mg of the compounds of formula (I) per day, optionally divided into multiple administrations.